Skip to main content

Table 2 Achieving fixed targets: the annual number of susceptible PWID who must be vaccinated for every reduction in treatments administered in order to maintain a specified reduction in prevalence

From: The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments

  

75 % relative prevalence reduction target

50 % relative prevalence reduction target

25 % relative prevalence reduction target

Time to target (years)

10

15

30

10

15

30

10

15

30

 

25 % initial chronic HCV prevalence among PWID

Vaccine efficacy

90 %

17.7

13.9

8.5

14.1

10.4

6.7

11.2

8.0

5.6

60 %

26.8

21.3

14.1

21.2

15.5

10.0

17.0

12.1

8.5

30 %

60.9

41.6

38.1

41.9

30.8

20.0

34.9

24.6

16.9

50 % initial chronic HCV prevalence among PWID

90 %

5.8

4.3

2.9

4.3

3.2

2.1

3.4

2.4

1.6

60 %

8.6

6.3

4.3

6.5

4.8

3.2

5.1

3.7

2.4

30 %

17.2

13.0

8.9

13.0

9.7

6.5

10.3

7.5

4.9

75 % initial chronic HCV prevalence among PWID

90 %

2.0

1.4

1.0

1.4

1.0

0.7

1.1

0.8

0.5

60 %

3.0

2.1

1.5

2.2

1.5

1.0

1.6

1.1

0.8

30 %

5.6

4.3

2.9

4.3

3.1

2.1

3.2

2.3

1.5

  1. HCV hepatitis C virus, PWID people who inject drugs